Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT04246047 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04246047
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-07
- Primary completion
- 2023-10-02
- Enrollment
- 494
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.